DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Choueiri TK, Hessel C, Halabi S. et al.
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
European journal of cancer 2018;
94: 115-125
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.